Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 finished strong and closed the week up 1%, while the Nasdaq gained 1.7%. Neither index has any remaining resistance as the S&P 500 continued further into all-time highs and the Nasdaq surpassed its 2021 peak of 16,212 for the first time. Indices have the first level of support at their 10-DMA (5,059/15,935). Below that, the 21-DMAs are the most major level of support (5,016/15,819). The distribution day count on each index stands at six, with one set to expire in the coming week.

O’Neil Health Care Weekly

XLV gained 1.5%, rallying for a fourth straight week as it trends along support at its 10-DMA ($145.41) and 21-DMA ($143.31). Despite
good absolute performance, we continue to recommend an equal-weight sector positioning as its RS line remains in a longer-term
downtrend versus the broader market.

O’Neil Health Care Weekly

XLV gained 1.1% last week continuing its move into new all-time highs. The 21-DMA ($142.42) has been acting as a solid level of
near-term support since November. The RS line has risen from lows, but has yet to make a higher high, warranting an equal-tounderweight sector positioning, which will likely change should the broader tape come under pressure.

Market View

The U.S. market remains in a Confirmed Uptrend. This week, the S&P 500 fell 0.4% while the Nasdaq fell 1.4%. Both indices bounced from 21-DMA support (4,936/15,582) but closed a bit off the highs established on Monday. The S&P 500 is still well into all-time highs while the Nasdaq is about 2% below its Q4 2021 peak (16,212). Indices are about 4% extended from their 50-DMA (4,813/15,134). The distribution day count stands at five and four, respectively, after each index picked two this week (Tuesday and Friday).

O’Neil Health Care Weekly

XLV gained 1.4% last week, pacing the S&P 500 and breaking into new all-time highs. The 21-DMA ($141.15) has been acting as a solid level of near-term support since November. Despite a steady trend higher, the RS line remains in a longer-term downtrend as Health Care leadership remains narrow and unable to keep up with the Tech heavy rally. We continue to recommend an equal-to underweight sector positioning, which will likely change should the broader tape come under pressure.

O’Neil Health Care Weekly

XLV rose 195bps last week, making a new 52-week high. Near-term support remains the rising 21-DMA ($139.51) with the next level of resistance at the all-time high of $143.42. Though technical action remains positive, the overall rally within the sector has been narrow. Further, its RS line remains in a longer-term downtrend, unable to make higher highs and still warranting an under-to-equal weight sector positioning.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq were up 1.4% and 1.1%, respectively, this week. The indices rose for a fourth week and for the thirteenth time in 14 weeks. Indices bounced from support at respective 21-DMAs (4,840/15,228) and once again made new 52-week (S&P 500 made all-time) highs to end the week. The distribution day count for both indices remains at six and three, respectively. However, four distribution days on the S&P 500 and two on the Nasdaq are set to expire next week.

O’Neil Health Care Weekly

XLV traded relatively flat last week, falling 14bps and testing support at its 21-DMA ($138.50). The sector is still consolidating with resistance between $141.56 and $143.42 (all-time highs). Its RS line pulled back sharply, warranting an under-to- equal-weight sector positioning.